{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:39:31Z","timestamp":1792172371683,"version":"4.4.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastric-type endocervical adenocarcinoma (GEA) is an aggressive, HPV-independent malignancy with a poor prognosis. Cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, has shown promising efficacy in advanced cervical cancer but may increase the risk of immune-related adverse events (irAEs), including rare multiorgan involvement. Reports of sequential, multiorgan irAEs involving the urinary tract and endocrine system following cadonilimab therapy, as well as subsequent successful rechallenge, are exceedingly rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 70-year-old female with stage IVB GEA developed concurrent irAEs nine months after initiating first-line chemotherapy combined with cadonilimab and bevacizumab. She initially presented with urinary frequency, urgency, and fatigue. Investigations revealed grade II immune-related cystitis (based on imaging and persistently negative urine cultures) and concurrent grade III adrenal insufficiency (AI) with low serum cortisol and inappropriately normal ACTH levels. Immunotherapy was temporarily suspended, and she commenced hydrocortisone replacement therapy, resulting in symptom amelioration. After symptom resolution, cadonilimab was rechallenged on August 16, 2025. Four months later, she developed diabetic ketoacidosis (DKA) and received a diagnosis of grade IV immune-related diabetes mellitus (DM), requiring insulin therapy. After metabolic stabilization, cadonilimab was rechallenged again. As of the last follow-up, the patient had received 24 cycles of cadonilimab, achieving a progression-free survival (PFS) of 17 months with no recurrence of prior irAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the rare but possible occurrence of sequential, multiorgan irAEs, including cystitis, AI, and DKA, following cadonilimab therapy. This case underscores the importance of multidisciplinary collaboration, vigilant monitoring, and individualized rechallenge decisions in managing complex irAEs. Importantly, it demonstrates that immunotherapy rechallenge can be feasible and provide sustained clinical benefit in selected patients with advanced GEA after resolution of severe irAEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1836563","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:45:20Z","timestamp":1779255920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Successful rechallenge of cadonilimab-induced cystitis, adrenal insufficiency, and diabetic ketoacidosis in a patient with metastatic gastric-type endocervical adenocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhan","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fengcheng People\u2019s Hospital, Yichun University","place":["Yichun, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaJin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Fengcheng People\u2019s Hospital, Yichun University","place":["Yichun, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fengcheng Maternal and Child Health Hospital","place":["Yichun, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WuGang","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Radiology, Fengcheng People\u2019s Hospital, Yichun University","place":["Yichun, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiYan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Fengcheng People\u2019s Hospital, Yichun University","place":["Yichun, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XueWen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University(Ganzhou People\u2019s Hospital)","place":["Ganzhou, Jiangxi, China"]},{"name":"Ganzhou Municipal Key Laboratory of Tumor Radiobiology, Ganzhou People\u2019s Hospital","place":["Ganzhou, Jiangxi, China"]},{"name":"The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000213434.91868.b0","article-title":"Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix","volume":"31","author":"Kojima","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.345","article-title":"Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance","volume":"10","author":"Sun","year":"2024","journal-title":"J Pathol Clin Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.3390\/ijms26157469","article-title":"A comparative analysis of usual- and gastric-type cervical adenocarcinoma in a Japanese population reveals distinct clinicopathological and molecular features with prognostic and therapeutic insights","volume":"26","author":"Zahan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.100323","article-title":"Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype","volume":"177","author":"Kusanagi","year":"2010","journal-title":"Am J Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5483\/bmbrep.2022.55.9.042","article-title":"Untold story of human cervical cancers: HPV-negative cervical cancer","volume":"55","author":"Lee","year":"2022","journal-title":"BMB Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.01.022","article-title":"Analysis of gastric-type mucinous carcinoma of the uterine cervix - an aggressive tumor with a poor prognosis: a multi-institutional study","volume":"153","author":"Nishio","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1386294","article-title":"State of the art of cervical cancer treatment in rare histologies","volume":"14","author":"Arango-Bravo","year":"2024","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3162","article-title":"Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study","volume":"30","author":"Lou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70741","article-title":"A real-word analysis of the correlation between clinical efficacy and predictive factors of immune-related adverse events in patients with nonsmall lung cancer treated with nivolumab plus ipilimumab","volume":"14","author":"Mouri","year":"2025","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011271","article-title":"Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations","volume":"13","author":"Wu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0459","article-title":"Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015-2019","volume":"43","author":"Liu","year":"2020","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0609","article-title":"Immune checkpoint inhibitor-associated diabetes: a single-institution experience","volume":"43","author":"Byun","year":"2020","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1727822","article-title":"Single-center experience with immune checkpoint inhibitor-related ureteritis and cystitis","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10238-026-02052-3","article-title":"Clinical characteristics and therapies of multi-organ immune related adverse events","volume":"26","author":"Wang","year":"2026","journal-title":"Clin Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7567","article-title":"Multiorgan immune-related adverse events during treatment with atezolizumab","volume":"18","author":"Kichenadasse","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_47_25","article-title":"Endocrine adverse events of immune checkpoint inhibitors: a comprehensive review","volume":"29","author":"Rajan","year":"2025","journal-title":"Indian J Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41574-024-01077-6","article-title":"Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors","volume":"21","author":"Iwama","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-017-0298-6","article-title":"A case of cystitis after administration of nivolumab","volume":"6","author":"Ozaki","year":"2017","journal-title":"Int Cancer Conf J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11619","DOI":"10.3390\/ijms262311619","article-title":"Beyond tumor immunity: the disruption of endocrine and infectious homeostasis by immune checkpoint inhibitors","volume":"26","author":"Sch\u00f6nberger","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/eje-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3390\/jcm9072033","article-title":"Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: a review","volume":"9","author":"Okura","year":"2020","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60850","article-title":"Adrenal insufficiency and thyrotoxicosis following combined immune checkpoint inhibitor use: a case report and literature review","volume":"16","author":"Fukushima","year":"2024","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172728","article-title":"Etiologies and outcomes of diabetic ketoacidosis in cancer patients: a retrospective analysis","volume":"17","author":"Gandhi","year":"2025","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/ec-18-0068","article-title":"Society for Endocrinology Endocrine Emergency Guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110414","article-title":"Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus","volume":"122","author":"Liao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1448728","article-title":"A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000030398","article-title":"Type 1 diabetes associated with immune checkpoint inhibitors for Malignant melanoma: a case report and review of 8 cases","volume":"101","author":"Ishiguro","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s40425-019-0713-y","article-title":"Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature","volume":"7","author":"Gunjur","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0000000000000807","article-title":"Endocrinopathies related to immune checkpoint inhibitors","volume":"26","author":"Khalid","year":"2019","journal-title":"Am J Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621858","article-title":"Immune-therapy-related toxicity events and dramatic remission after a single dose of pembrolizumab treatment in metastatic thymoma: a case report","volume":"12","author":"Shen","year":"2021","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.993622","article-title":"Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: a case report and review of literature","volume":"13","author":"Hino","year":"2022","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000036664","article-title":"Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: a case report","volume":"102","author":"Iesaka","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0880-8","article-title":"Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis","volume":"21","author":"Sum","year":"2018","journal-title":"Pituitary"},{"key":"B44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocr Soc"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1159\/000510044","article-title":"Type 1 diabetes, ACTH deficiency, and hypothyroidism simultaneously induced by nivolumab therapy in a patient with gastric cancer: a case report","volume":"13","author":"Marshall","year":"2020","journal-title":"Case Rep Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1036603","article-title":"Multisystem immune-related adverse events due to toripalimab: two cases-based review","volume":"9","author":"Chen","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2020.04.006","article-title":"Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: a case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma","volume":"15","author":"Fuentes-Antr\u00e1s","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13573","article-title":"Autoimmune polyendocrine syndrome type 3, characterized by autoimmune thyroid disease, type 1 diabetes mellitus, and isolated ACTH deficiency, developed during adjuvant nivolumab treatment","volume":"18","author":"Takata","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"665784428","DOI":"10.1177\/03000605221121940","article-title":"Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases","volume":"50","author":"Luo","year":"2022","journal-title":"J Int Med Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.55729\/2000-9666.1270","article-title":"When hormones are being difficult: a rare case and the literature review of pembrolizumab-induced polyendocrinopathy","volume":"13","author":"Tayyeb","year":"2023","journal-title":"J Community Hosp Internal Med Perspect"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0000000000001681","article-title":"Immune-mediated diabetes mellitus, diabetic ketoacidosis, enteritis, and thrombotic thrombocytopenic purpura presenting as adverse effects of pembrolizumab therapy","volume":"31","author":"Luong","year":"2024","journal-title":"Am J Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90424","article-title":"Multisystem immune-related adverse events following pembrolizumab: a critical care case of myocarditis, diabetic ketoacidosis, and CNS demyelination","volume":"17","author":"Janulevicius","year":"2025","journal-title":"Cureus"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.94583","article-title":"A triple threat: Immune checkpoint inhibitor-induced diabetic ketoacidosis, myocarditis, and adrenal insufficiency in a patient with metastatic melanoma","volume":"17","author":"Nur","year":"2025","journal-title":"Cureus"},{"key":"B54","doi-asserted-by":"publisher","first-page":"luag024","DOI":"10.1210\/jcemcr\/luag024","article-title":"Multigland dysfunction from immune-checkpoint inhibitors: a case of hypothyroidism, diabetes, and adrenal insufficiency","volume":"4","author":"Vengilote","year":"2026","journal-title":"JCEM Case Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"251","DOI":"10.21037\/atm-21-7006","article-title":"Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study","volume":"10","author":"Cui","year":"2022","journal-title":"Ann Transl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1836563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:45:29Z","timestamp":1779255929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1836563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":59,"alternative-id":["10.3389\/fonc.2026.1836563"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1836563","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1836563"}}